Illumina (ILMN)
(Delayed Data from NSDQ)
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 50% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Is a Surprise Coming for Illumina (ILMN) This Earnings Season?
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Markets' Tone: Cautiously Optimistic
by Daniel Laboe
As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds
Illumina (ILMN) to Address Nasopharynx Cancer With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will fuel initiatives that enhance health outcomes for people living with nasopharynx cancer and advance the development of personalized treatment.
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Here's Why You Should Hold on to Illumina (ILMN) for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) owing to its strength in international markets and notable strategic partnerships.
Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Company News for Jan 12, 2022
by Zacks Equity Research
Companies in The News Are: ACCD,PACB,BIG,ILMN
Illumina (ILMN) Announces Preliminary Q4 Sales, Issues '22 View
by Zacks Equity Research
Illumina's (ILMN) preliminary fourth-quarter results, latest partnership deals and a robust pipeline of technologies instill investor optimism.
Illumina (ILMN)-SomaLogic Ink Deal to Advance Proteomics
by Zacks Equity Research
Illumina's (ILMN) collaboration with SomaLogic will boost the fast-growing high throughput sector of the proteomics market to aid research in biology and disease.
Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.
4 Toxic Stocks to Eliminate From Your Portfolio Now
by Rimmi Singhi
Detecting toxic stocks and dumping them at the right time is crucial to avoid big losses. ILMN, TCMD, CTOS and GCI are a few toxic stocks that don't deserve a place in your portfolio.
Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
by Zacks Equity Research
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
Don't Squander Your Income on These 3 Toxic Stocks
by Rimmi Singhi
Precisely figuring out toxic stocks and discarding or short selling those at the right time is the key to safeguarding your portfolio from big losses.
Illumina's (ILMN) New Alliance to Accelerate Genomics in China
by Zacks Equity Research
Illumina's (ILMN) Genomics Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics.
Illumina (ILMN) iHope Genetic Health Program Expands WGS Access
by Zacks Equity Research
Illumina's (ILMN) launch of iHope Genetic Health program will expand access to WGS to low- and middle-income communities worldwide.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up
by Zacks Equity Research
Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.
Illumina (ILMN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 16.94% and 6.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Will Christmas Come Early For Investors This Year?
by Daniel Laboe
Welcome to November, the seasonally strongest month for S&P 500 returns, averaging growth of 2.5% over the past decade